Immediate Amelioration of Severe Respiratory Distress in Sjögren's Syndrome with COVID-19 Treated with a Single Dose of Off-label Tocilizumab

The coronavirus disease 2019 (COVID-19) pandemic has become an urgent global health issue. An older age and underlying conditions, such as diabetes, have been reported as risk factors, but whether or not autoimmune diseases increase the risk remains unknown. An 85-year-old man with Sjögren's sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Kataoka, Hiroshi, Kodama, Fumihiro, Tomita, Tomoko, Kondo, Makoto, Nagasaka, Atsushi, Nishikawa, Shuji, Mukai, Masaya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946515/
https://www.ncbi.nlm.nih.gov/pubmed/33390490
http://dx.doi.org/10.2169/internalmedicine.6010-20
_version_ 1783663067750465536
author Kataoka, Hiroshi
Kodama, Fumihiro
Tomita, Tomoko
Kondo, Makoto
Nagasaka, Atsushi
Nishikawa, Shuji
Mukai, Masaya
author_facet Kataoka, Hiroshi
Kodama, Fumihiro
Tomita, Tomoko
Kondo, Makoto
Nagasaka, Atsushi
Nishikawa, Shuji
Mukai, Masaya
author_sort Kataoka, Hiroshi
collection PubMed
description The coronavirus disease 2019 (COVID-19) pandemic has become an urgent global health issue. An older age and underlying conditions, such as diabetes, have been reported as risk factors, but whether or not autoimmune diseases increase the risk remains unknown. An 85-year-old man with Sjögren's syndrome developed a severe COVID-19 infection that required oxygen supplementation. After discussing the goals of care with him and his wife, off-label tocilizumab was given concomitantly, resulting in a rapid improvement in his symptoms and respiratory failure. This patient represents a supplementary case confirming the efficacy and safety of tocilizumab for COVID-19 in elderly patients with autoimmune diseases.
format Online
Article
Text
id pubmed-7946515
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-79465152021-03-15 Immediate Amelioration of Severe Respiratory Distress in Sjögren's Syndrome with COVID-19 Treated with a Single Dose of Off-label Tocilizumab Kataoka, Hiroshi Kodama, Fumihiro Tomita, Tomoko Kondo, Makoto Nagasaka, Atsushi Nishikawa, Shuji Mukai, Masaya Intern Med Case Report The coronavirus disease 2019 (COVID-19) pandemic has become an urgent global health issue. An older age and underlying conditions, such as diabetes, have been reported as risk factors, but whether or not autoimmune diseases increase the risk remains unknown. An 85-year-old man with Sjögren's syndrome developed a severe COVID-19 infection that required oxygen supplementation. After discussing the goals of care with him and his wife, off-label tocilizumab was given concomitantly, resulting in a rapid improvement in his symptoms and respiratory failure. This patient represents a supplementary case confirming the efficacy and safety of tocilizumab for COVID-19 in elderly patients with autoimmune diseases. The Japanese Society of Internal Medicine 2020-12-29 2021-02-15 /pmc/articles/PMC7946515/ /pubmed/33390490 http://dx.doi.org/10.2169/internalmedicine.6010-20 Text en Copyright © 2021 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Kataoka, Hiroshi
Kodama, Fumihiro
Tomita, Tomoko
Kondo, Makoto
Nagasaka, Atsushi
Nishikawa, Shuji
Mukai, Masaya
Immediate Amelioration of Severe Respiratory Distress in Sjögren's Syndrome with COVID-19 Treated with a Single Dose of Off-label Tocilizumab
title Immediate Amelioration of Severe Respiratory Distress in Sjögren's Syndrome with COVID-19 Treated with a Single Dose of Off-label Tocilizumab
title_full Immediate Amelioration of Severe Respiratory Distress in Sjögren's Syndrome with COVID-19 Treated with a Single Dose of Off-label Tocilizumab
title_fullStr Immediate Amelioration of Severe Respiratory Distress in Sjögren's Syndrome with COVID-19 Treated with a Single Dose of Off-label Tocilizumab
title_full_unstemmed Immediate Amelioration of Severe Respiratory Distress in Sjögren's Syndrome with COVID-19 Treated with a Single Dose of Off-label Tocilizumab
title_short Immediate Amelioration of Severe Respiratory Distress in Sjögren's Syndrome with COVID-19 Treated with a Single Dose of Off-label Tocilizumab
title_sort immediate amelioration of severe respiratory distress in sjögren's syndrome with covid-19 treated with a single dose of off-label tocilizumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946515/
https://www.ncbi.nlm.nih.gov/pubmed/33390490
http://dx.doi.org/10.2169/internalmedicine.6010-20
work_keys_str_mv AT kataokahiroshi immediateameliorationofsevererespiratorydistressinsjogrenssyndromewithcovid19treatedwithasingledoseofofflabeltocilizumab
AT kodamafumihiro immediateameliorationofsevererespiratorydistressinsjogrenssyndromewithcovid19treatedwithasingledoseofofflabeltocilizumab
AT tomitatomoko immediateameliorationofsevererespiratorydistressinsjogrenssyndromewithcovid19treatedwithasingledoseofofflabeltocilizumab
AT kondomakoto immediateameliorationofsevererespiratorydistressinsjogrenssyndromewithcovid19treatedwithasingledoseofofflabeltocilizumab
AT nagasakaatsushi immediateameliorationofsevererespiratorydistressinsjogrenssyndromewithcovid19treatedwithasingledoseofofflabeltocilizumab
AT nishikawashuji immediateameliorationofsevererespiratorydistressinsjogrenssyndromewithcovid19treatedwithasingledoseofofflabeltocilizumab
AT mukaimasaya immediateameliorationofsevererespiratorydistressinsjogrenssyndromewithcovid19treatedwithasingledoseofofflabeltocilizumab

Ejemplares similares